Post by George Syrmalis M.D Ph.D FRSM

One of the questions I am often asked is what separates biotech companies that successfully attract institutional capital from those that struggle despite excellent science. The answer is rarely the science alone. Successful capital raising requires a combination of scientific validation, commercial strategy, regulatory readiness, disciplined execution, and management teams capable of navigating a long and complex development journey. I recently had the opportunity to discuss these topics, along with the future of biotechnology investing, precision medicine, AI-driven drug discovery, and the evolution of global life science capital markets, in an interview with Arabian Business Times. I hope the discussion provides useful insights for founders, investors, and others working to translate scientific innovation into successful companies. Interview: https://lnkd.in/dfenfshs #Biotechnology #LifeSciences #HealthcareInnovation #VentureCapital #InvestmentBanking #MedTech #PrecisionMedicine #DrugDiscovery